
|Videos|April 4, 2023
Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC
Dr Jason Porter presents safety and efficacy data from a Phase 1/2 study on mobocertinib in patients with mNSCLC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5



















